Clinical trial
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular…
NCT00105443 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00105443 |
|---|---|
| Title | A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
| Official title | A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
| Acronym | SHARP |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo |
| Enrollment | 602 |
| Start date | Mar 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Mar 15, 2005 |
| Last update posted | Oct 31, 2014 |
| Countries | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, France, Germany, Greece, Israel and 11 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: